Differentiating Molecular Risk Assessments for Prostate Cancer.
Publication/Presentation Date
1-1-2018
Abstract
It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of "significant" prostate cancer. Herein we discuss these tests and their clinical implications.
Volume
20
Issue
1
First Page
12
Last Page
18
ISSN
1523-6161
Published In/Presented At
Press, B., Schulster, M., & Bjurlin, M. A. (2018). Differentiating Molecular Risk Assessments for Prostate Cancer. Reviews in urology, 20(1), 12–18. https://doi.org/10.3909/riu0787
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
29942196
Department(s)
Department of Pediatrics, Department of Surgery
Document Type
Article